A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
NCT ID: NCT06060977
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
29 participants
INTERVENTIONAL
2023-09-25
2025-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PF-06651600 for the Treatment of Alopecia Areata
NCT03732807
ENERGI-F701 for Female Hair Loss Treatment
NCT03351322
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
NCT02974868
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
NCT01325337
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IMG-007 Dose 1
IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
IMG-007
Intravenous Infusion
IMG-007 Dose 2
IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
IMG-007
Intravenous Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMG-007
Intravenous Infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AA with current episode of hair loss of \> 6 months but \< 8 years
* AA with ≥ 50% scalp involvement as defined as SALT score ≥ 50
Exclusion Criteria
* Evidence of active or latent tuberculosis (TB)
* History of untreated or inadequately treated TB infection.
* Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit
* Concurrent hair loss due to other etiologies
* Primary "diffuse" type of AA
* Active inflammatory diseases on the scalp that would interfere with the assessment of AA
* History or presence of hair transplants or micropigmentation of the scalp
* Active systemic diseases that may cause hair loss
* Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inmagene LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A.
Rogers, Arkansas, United States
Torrance Clinical Research Institute Inc.
Lomita, California, United States
Alliance Clinical Research of Tampa
Tampa, Florida, United States
Dawes Fretzin Clinical Resarch Group, LLC
Indianapolis, Indiana, United States
Options Research Group
West Lafayette, Indiana, United States
Lahey Hospital & Medical Center
Burlington, Massachusetts, United States
Great Lakes Research Group Inc.
Bay City, Michigan, United States
Skin Cancer and Dermatology Institute
Reno, Nevada, United States
Skin Search of Rochester, Inc.
Rochester, New York, United States
Stride Clinical Research LLC
Sugar Land, Texas, United States
Dermatology Specialists of Spokane
Spokane, Washington, United States
SimcoMed Health Ltd.
Barrie, Ontario, Canada
Skin Health
Cobourg, Ontario, Canada
Guelph Dermatology Research
Guelph, Ontario, Canada
Research Toronto
Toronto, Ontario, Canada
Centre de Recherche Saint-Louis
Québec, Quebec, Canada
Innovaderm Research Inc.
Montreal, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMG-007-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.